Work

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet. Gastroenterology & hepatology

DOI: 10.1016/s2468-1253(25)00067-6

Authors: Rohit Loomba, Kris V Kowdley, Jose Rodriguez, Nomita J Kim, Alina Maria Alvarez, Linda Morrow, Brenda Jeglinski, Alicia Clawson, Swapan Chowdhury, Gerard Bain, Tatjana Odrljin

Institutions: University of California San Diego, Washington State University Spokane, Liver Institute Northwest, The University of Texas at Austin, Boston Pharmaceuticals (United States)

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Boston Pharmaceuticals

OpenAlex ID: W4411049873

FWCI: 18

Cites: 26

Cited by: 52

Related to: 10